Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Dreieich – page 6

1 481 clinical trials in Dreieich, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Dreieich at a glance
1 481
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 481 trials in Dreieich

Open in trial search

Study on Managing Heart Attack Risk with Icosapent Ethyl and Drug Combination for Patients at High Risk of Another Heart Attack

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Medical University Of Graz

Colitis ulcerative+1

Recruiting

Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn's Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Study on the Safety and Effectiveness of BNT327 with Chemotherapy for Patients with Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:BioNTech SE

Crohn's disease

Recruiting

Study of RO7790121 (afimkibart) for Treatment and Long-term Management in Adults with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Study on the Effects of Baxdrostat and Dapagliflozin in Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Eltrekibart
  • Sponsor:Eli Lilly & Co.

Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Study on the Effects of Pegozafermin for Patients with Nonalcoholic Steatohepatitis (NASH) and Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BIO89-100
  • Sponsor:F. Hoffmann-La Roche AG

Study on Lebrikizumab for Adults with Chronic Rhinosinusitis and Nasal Polyps Using Intranasal Corticosteroids

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lebrikizumab
  • Sponsor:Eli Lilly & Co.

Dermatomyositis+1

Recruiting

Study on Anifrolumab for Adults with Polymyositis or Dermatomyositis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Dreieich

What the registry says about research in the country

01 Allergy Research

Clinical trials focusing on innovative treatments for allergic rhinoconjunctivitis, particularly targeting birch pollen and house dust mite allergies.

  • Birch Pollen Allergies
  • House Dust Mite Sensitivity
  • Immunotherapy Development

Research includes evaluation of subcutaneous immunotherapy treatments and novel allergoid formulations.

02 Pediatric Allergology

Dedicated studies examining the safety and efficacy of STALORAL® treatments in children and adolescents with seasonal allergies.

  • Child-Specific Treatments
  • Age-Appropriate Dosing
  • Safety Monitoring

Special focus on developing safe and effective treatments for young patients aged 5-17 years.

03 Respiratory Medicine

Comprehensive research into moderate to severe allergic conditions affecting the respiratory system, including asthma complications.

  • Combined Symptom Management
  • Therapeutic Efficacy
  • Long-term Treatment Outcomes

Studies evaluate both symptomatic relief and long-term disease modification approaches.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.